Skip to main content

The Globe and Mail

Neurochem plummets as clinical trial flops

Shares in Neurochem Inc. plummeted by more than 40 per cent yesterday on news that its would-be blockbuster drug to fight Alzheimer's disease was a bust in a key clinical trial.

Neurochem stock plunged $2.56 - almost 44 per cent - to close at $3.30 on the Toronto Stock Exchange, after the Laval, Que.-based drug developer said on Sunday that results from its Phase III trial in North America "did not demonstrate a statistically significant difference" on patients.

The news confirmed speculation among many analysts over the past few months that the drug - Alzhemed - was not the silver bullet investors had been hoping for.

Story continues below advertisement

Analyst Eun Yang of Jefferies and Co. dropped coverage of Neurochem yesterday. Another analyst, David Dean of Cormark Securities Inc., wrote in a research note: "While the writing has been on the wall for many months that this Alzhemed trial has failed, it appears to us that Neurochem has no viable programs left."

Neurochem said that the U.S. Food and Drug Administration rejected a proposed adjustment to the trial's original statistical model, thus resulting in the inconclusive data.

The testing involved 1,052 patients suffering from mild-to-moderate Alzheimer's disease at 67 locations in Canada and the U.S.

The company also said it has established a special advisory board to mull future options and still hopes to modify its study design for Phase III trials in Europe.

Report an error Licensing Options
About the Author
Quebec Business Correspondent

Bertrand has been covering Quebec business and finance since 2000. Before joining The Globe and Mail in 2000, he was the Toronto-based national business correspondent for Southam News. He has a B.A. from McGill University and a Bachelor of Applied Arts from Ryerson. More


The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨